Is Meftal Spas (mefenamic acid) safe to use in patients with dengue?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 8, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Safety of Meftal Spas (Mefenamic Acid) in Dengue Fever

Meftal Spas (mefenamic acid) should NOT be used in patients with dengue fever due to increased risk of bleeding complications.

Rationale for Avoiding NSAIDs in Dengue

Dengue fever is characterized by thrombocytopenia (low platelet count) which increases bleeding risk. Multiple guidelines specifically contraindicate NSAIDs like mefenamic acid in dengue management:

  • The World Health Organization and US Centers for Disease Control recommend acetaminophen/paracetamol for pain and fever management in dengue while specifically contraindicating NSAIDs due to potential bleeding risk 1.

  • Praxis Medical Insights clearly states: "Avoid NSAIDs, as they may worsen bleeding risk, and use acetaminophen/paracetamol instead for fever control" with a high strength of evidence level 2.

Bleeding Risk in Dengue

Dengue patients are at significant risk for bleeding complications:

  • A study of 638 dengue patients found a 24.1% prevalence of bleeding tendencies, with prior anti-platelet drug intake significantly increasing bleeding risk 3.

  • Thrombocytopenia, leukopenia, and raised hematocrit levels are the most significant hematological parameters when assessing dengue severity 4.

  • Patients with severe dengue commonly experience mucosal bleeding (71.4%), fluid accumulation (57.1%), shock (35.7%), and gastrointestinal bleeding (28.6%) 4.

Mechanism of Increased Risk

Mefenamic acid (Meftal Spas) is an NSAID that inhibits platelet aggregation through its effect on cyclooxygenase enzymes. This anti-platelet effect compounds the already compromised hemostatic function in dengue patients who typically have:

  1. Thrombocytopenia (platelet counts often <70,000/mm³)
  2. Coagulation abnormalities (elevated INR >2.0 and PTT >60 seconds) 3
  3. Potential endothelial damage from the virus

Alternative Management Options

For Pain and Fever Control:

  • First-line: Acetaminophen/paracetamol is the recommended analgesic and antipyretic 2, 1
  • Dosing: Standard dosing based on age and weight, not exceeding maximum daily limits

For Fluid Management:

  • Fluid resuscitation is critical in dengue management:
    • For patients with shock: Initial fluid bolus of 20 mL/kg with subsequent reassessment 5
    • For patients without shock: Maintenance fluids without bolus administration 5

Special Considerations

Monitoring Requirements:

  • Daily complete blood count to track hemoglobin/hematocrit trends and platelet count 2
  • Regular monitoring of vital signs and clinical assessment for warning signs 2
  • Assessment for bleeding manifestations

Warning Signs Requiring Urgent Attention:

  • Abdominal pain
  • Persistent vomiting
  • Clinical fluid accumulation
  • Mucosal bleeding
  • Lethargy
  • Liver enlargement >2 cm 2

Emerging Research

While some recent research suggests that low-dose ibuprofen might be comparable to acetaminophen in non-severe dengue 6, this evidence is preliminary and contradicts established guidelines. A systematic review found no evidence supporting any interventions for preventing or treating clinically significant bleeding in dengue 7.

Conclusion

Until stronger evidence emerges, the safest approach is to avoid Meftal Spas (mefenamic acid) in dengue patients and use acetaminophen/paracetamol instead for symptom management. The risk of bleeding complications outweighs any potential benefits of NSAIDs in this population.

References

Guideline

Management of Anemia in Dengue Fever and Other Hematological Conditions

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Prevalence, patterns, and factors associated with bleeding tendencies in dengue.

Journal of infection in developing countries, 2015

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Prophylactic and therapeutic interventions for bleeding in dengue: a systematic review.

Transactions of the Royal Society of Tropical Medicine and Hygiene, 2017

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.